Postmenopausal female hormone use and estrogen receptor-positive and -negative breast cancer in african American women

Journal of the National Cancer Institute

Volumn 108, Issue 4, 2016, Pages

  Rosenberg, Lynn ^a   Bethea, Traci N ^a   Viscidi, Emma ^a   Hong, Chi Chen ^b   Troester, Melissa A ^c   Bandera, Elisa V ^d   Haiman, Christopher A ^e   Kolonel, Laurence N ^f   Olshan, Andrew F ^c   Ambrosone, Christine B ^b   Palmer, Julie R ^a  

^a BOSTON UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ESTROGEN RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CONTROLLED STUDY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; PATIENT HISTORY OF BILATERAL OVARIECTOMY; PATIENT HISTORY OF HYSTERECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; ADVERSE EFFECTS; BREAST NEOPLASMS; CHEMICALLY INDUCED; CHEMISTRY; ESTROGEN THERAPY; MIDDLE AGED; ODDS RATIO; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PROGESTINS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84964857146     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv361     Document Type: Article

References (44)

1. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-1059.
2. Schairer C, Lubin J, Troisi R, et al. Estrogen-progestin replacement and risk of breast cancer. JAMA. 2000;284(6):691-694.
3. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24):1589-1593.
4. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long term oestrogen- And oestrogen-progestin-replacement therapy. Int J Cancer. 1999;81(3):339-344.
5. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328-332.
6. Fournier A, Mesrine S, Dossus L, et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat. 2014;145(2):535-543.
7. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427.
8. Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology- And hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26(8):1260-1268.
9. Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3150-3160.
10. Hulley S, Furberg C, Barrett-Connor E, et al. Non cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58-66.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
12. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692.
13. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573-587.
14. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
15. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006;166(9):1027-1032.
16. Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: A large prospective cohort study. Breast Cancer Res. 2012;14(3):R76.
17. Hou N, Hong S, Wang W, et al. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013;105(18):1365-1372.
18. Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296-305.
19. Rosenberg L, Palmer JR, Wise LA, et al. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med. 2006;166(7):760- 765.
20. Cui Y, Deming-Halverson SL, Shrubsole MJ, et al. Associations of hormonerelated factors with breast cancer risk according to hormone receptor status among white and african american women. Clin Breast Cancer .2014;14(6):417-425.
21. Hall IJ, Moorman PG, Millikan RC, et al. Comparative analysis of breast cancer risk factors among African-American women and White women. Am J Epidemiol. 2005;161(1):40-51.
22. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol. 2002;100(6):1148- 1158.
23. Palmer JR, Ambrosone CB, Olshan AF. A collaborative study of the etiology of breast cancer subtypes in African American women: The AMBER consortium. Cancer Causes Control. 2013;25(3):309-319.
24. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139.
25. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151(4):346- 357.
26. Ambrosone CB, Ciupak GL, Bandera EV, et al. Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women. J Oncol. 2009;10.1155/2009/871250:1-15.
27. Bandera EV, Chandran U, Zirpoli G, et al. Rethinking sources of representative controls for the conduct of case-control studies in minority populations. BMC Med Res Methodol. 2013;13:71.
28. Gapstur SM, Dupuis J, Gann P, et al. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13, 239 cases. Cancer. 1996;77(8):1465-1471.
29. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol. 2009;76(1):44-52.
30. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: Age-specific prevalence and survival. J Surg Res. 2007;143(1):109-118.
31. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97(6):439-448.
32. Rosenberg L, Palmer JR, Rao RS, et al. Correlates of postmenopausal female hormone use among black women in the United States. Obstet Gynecol. 1998;91(3):454-458.
33. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004;104(5 Pt 1):1042-1050.
34. Wei F, Miglioretti DL, Connelly MT, et al. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr. 2005;2005(35):106- 112.
35. Clarke CA, Glaser SL, Uratsu CS, et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006;24(33):e49-e50.
36. Fournier A, Mesrine S, Boutron-Ruault MC, et al. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol. 2009;27(31):5138- 5143.
37. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.
38. Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015;1(3):296-305.
39. Chlebowski RT, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012;104(7):517-527.
40. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670- 1674.
41. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007;25(23):3437-3439.
42. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486.
43. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology: 3rd Edition. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008.
44. Banks E, Beral V, Cameron R, et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat. 2001;6(4):357- 363.